This aspect underlies the current interest in identifying key angiogenic players (ex., PDGF, SCF, ILs, TGF-β) that could serve as therapeutic targets capable of shutting off the tumor’s angiogenic “on” switch [68]. Here, TGFB1 is linked to neoplasm.